ASCO 2019: Atezolizumab + Bevacizumab Versus Sunitinib in Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Histology: IMmotion151 Subgroup Analysis – Medical Oncologist Perspective
ASCO 2019 IMmotion 151, atezolizumab plus bevacizumab versus sunitinib, patients with mRCC, proven strategy for patients with mRCC, sarcomatoid histology, patients with sarcomatoid features.